Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.07.28.21261285: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources All statistical analyses were performed using Stata 16.0 (StataCorp, College Station, TX, USA). StataCorpsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The main limitation of the study is the comparatively small amount of person-time participants …
SciScore for 10.1101/2021.07.28.21261285: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources All statistical analyses were performed using Stata 16.0 (StataCorp, College Station, TX, USA). StataCorpsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The main limitation of the study is the comparatively small amount of person-time participants contributed with one dose of vaccine only. This is likely the result of the short (three weeks) recommended interval between BNT162b2 mRNA vaccine doses at the time of the study. This makes the confidence intervals around the estimates of vaccine effectiveness associated with one dose of vaccine very broad. A further limitation was the lack of information available as part of the surveillance data beyond age, sex, and history of past infection of the residents. This prevented us from identifying whether some co-morbidities were associated with severe forms of disease. The study was conducted shortly after BNT162b2 mRNA COVID-19 vaccine campaigns were initiated for LTCF residents in early 2021. As vaccine-related immunity is expected to decline more quickly in the older compared to the younger population,27 these breakthrough events four to six weeks after the second dose of vaccines advocate for the administration of a third dose in the fall prior to an expected increase in SARS-CoV-2 circulation this coming winter in the northern hemisphere. Overall, our findings provide an important contribution to understanding the impact of B.1.351 lineage on the effectiveness of BNT162b2 mRNA COVID-19 vaccine in LTCFs. Vaccine effectiveness against B.1.351 was reduced, and we observed B.1.351 outbreaks with severe forms of disease among fully vaccinated individuals in two LTCFs. Our findings hi...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
